Page last updated: 2024-10-18

hydrogen and Amentia

hydrogen has been researched along with Amentia in 3 studies

Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.
dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.

Research Excerpts

ExcerptRelevanceReference
" Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity."3.71Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001)
"To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects."3.69Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Constans, JM1
Meyerhoff, DJ1
Gerson, J1
MacKay, S1
Norman, D1
Fein, G1
Weiner, MW1
Ernst, T1
Chang, L2
Melchor, R1
Mehringer, CM1
Huang, W1
Alexander, GE1
Shetty, HU1
Krasuski, JS1
Rapoport, SI1
Schapiro, MB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161]Phase 412 participants (Actual)Interventional2007-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase Monotherapy vs Combination of Memantine and Cholinesterase Inhibitor

Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks

Interventionratio (normalized to T2-corrected water (Mean)
Change in NAA [(t2-t1) - (t1-t0)]Change in Cr [(t2-t1) - (t1-t0)]Change in Cho [(t2-t1) - (t1-t0)]Change in mI [(t2-t1) - (t1-t0)]Change in NAA/Cr [(t2-t1) - (t1-t0)]Change in Cho/Cr [(t2-t1) - (t1-t0)]Change in mI/Cr [(t2-t1) - (t1-t0)]Change in NAA/Cho [(t2-t1) - (t1-t0)]Change in NAA/mI [(t2-t1) - (t1-t0)]
Memantine-54-2916-0.090.020.04-0.26-0.35

Other Studies

3 other studies available for hydrogen and Amentia

ArticleYear
H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
    Radiology, 1995, Volume: 197, Issue:2

    Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases; Brain Ischemia; Case-Control Studies;

1995
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
    Radiology, 1997, Volume: 203, Issue:3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female;

1997
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
    Neurology, 2001, Aug-28, Volume: 57, Issue:4

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre

2001